Orthogonal Ubiquitin Transfer to Profile E3 Substrate Specificity
Orthogonal Ubiquitin Transfer to Profile E3 Substrate Specificity
批准号:
9763580
负责人:
HIROAKI KIYOKAWA
金额:
$39.87万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-01-01 至 2022-06-30
关键词:
AffinityAntineoplastic AgentsAutoimmune DiseasesBacteriophagesBindingBiological ProcessCancer BiologyCell CycleCell Cycle RegulationCell Signaling ProcessCell surfaceCellsCellular biologyChimera organismComplexCreativenessCytokinesisDataDevelopmentDiseaseEngineeringEnzymesFundingGoalsGrantKnowledgeLeadLocationMalignant NeoplasmsMapsMediatingMethodsMissionMonitorMutationNatural Killer CellsNerve DegenerationNetwork-basedOutcomeParkinson DiseasePathogenesisPathway interactionsPlug-inPositioning AttributePost-Translational Protein ProcessingProtein EngineeringProteinsPublic HealthReactionRegulationResearchResearch PersonnelRoleSignal TransductionSubstrate SpecificityTestingTumor SuppressionUBE3A geneUbiquitinUbiquitinationUnited States National Institutes of HealthWorkYeastsbasecancer cellcross reactivitydesigneffective therapyinhibitor/antagonistinnovationinterestmulticatalytic endopeptidase complexparkin gene/proteinrecruitubiquitin ligaseubiquitin-protein ligase
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary / Abstract
Ubiquitin (UB) transfer through the E1-E2-E3 cascade mediates signal transduction in almost all aspects of
cell biology. E3 UB ligases catalyze UB transfer from E2s to the substrate proteins and ultimately decide the
targets, location, and timing of the ubiquitination reaction. Identifying the substrate proteins is the key to
elucidating the biological functions of an E3. However, its has been a significant challenge to profile E3 substrate
specificity because of the transient formation of E3-substrate complex and the cross-reactivity among various
E3s. Our long-term goal is to elucidate the important roles of E3-catalyzed protein ubiquitination in cell biology
and diseases. Working toward this goal, we developed a method that we called “orthogonal UB transfer (OUT)”
to identify the direct ubiquitination targets of an E3. In this innovative method, an engineered UB (xUB) is
exclusively transferred through an engineered cascade of xE1-xE2-xE3 to the substrates of a specific E3 (“x”
designates engineered enzymes free of cross creativities with native partners in the cell). We have constructed
OUT cascades of HECT E3 E6AP and U-box E3 E4B and CHIP to profile their substrate specificities and
validated OUT as an efficient platform to identify E3 substrates. The objective of this application is to generate
OUT cascades with Ring E3s Cbl-b and Parkin to identify their substrate proteins. We will also follow the leads
in the substrate profiles of E6AP and CHIP generated by OUT to establish the roles of these E3s in cell cycle
and cancer cell invasion. Our central hypothesis is that the OUT cascades of E3s can identify new regulatory
relationships between the E3 and substrates and elucidate the roles of E3 in cell signaling. Such a hypothesis is
supported by our strong preliminary data demonstrating the feasibility of OUT in profiling the ubiquitination
targets of E6AP, E4B, and CHIP. The rationale of our proposed work is that the 600 Ring E3s in the cell used a
highly homologous Ring domain to bind to E2 and mediate UB transfer from E2 to their substrate proteins. Once
we develop OUT platform with Ring E3s Cbl-b and Parkin, we can use similar protein engineering strategies to
build the OUT platform for other Ring E3s to reveal their biological functions. We will pursue three specific aims:
1) Extending the OUT cascades to Ring E3s Cbl-b and Parkin to profile their substrate proteins; 2) Extending
the OUT cascade to BRUCE to investigate its role in cytokinesis; 3) Studying the function of E6AP and CHIP
based on their substrate profile generated by OUT. The expected outcome of our work is the development of the
OUT platform to profile ubiquitination targets of all class of E3s including HECT, U-box and Ring types. Based
on the knowledge of their substrate specificity, we will elucidate the role of Cbl-b in regulating NK cell activity
against cancer cells, reveal the mechanism of Parkin in tumor suppression, and define the role the BRUCE in
cytokinesis. We will establish new cellular circuits mediated by E6AP and CHIP in cell cycle control and cancer
cell invasion. The positive impact of our work is that we will develop the OUT platform for other researchers to
plug in their E3s of interest and map the E3s on the cell signaling network by profiling their substrate specificity.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Orthogonal Ubiquitin Transfer to Profile E3 Substrate Specificity
-
批准号:8867257
-
项目类别:
-
资助金额:$29.98万
-
财政年份:2013
-
负责人:HIROAKI KIYOKAWA
-
依托单位:
Orthogonal Ubiquitin Transfer to Profile E3 Substrate Specificity
-
批准号:8819281
-
项目类别:
-
资助金额:$20.32万
-
财政年份:2013
-
负责人:HIROAKI KIYOKAWA
-
依托单位:
Orthogonal Ubiquitin Transfer to Profile E3 Substrate Specificity
-
批准号:9811405
-
项目类别:
-
资助金额:$2.63万
-
财政年份:2013
-
负责人:HIROAKI KIYOKAWA
-
依托单位:
Orthogonal Ubiquitin Transfer to Profile E3 Substrate Specificity
-
批准号:8422446
-
项目类别:
-
资助金额:$12.15万
-
财政年份:2013
-
负责人:HIROAKI KIYOKAWA
-
依托单位:
Orthogonal Ubiquitin Transfer to Profile E3 Substrate Specificity
-
批准号:8601117
-
项目类别:
-
资助金额:$29.98万
-
财政年份:2013
-
负责人:HIROAKI KIYOKAWA
-
依托单位:
Orthogonal Ubiquitin Transfer to Profile E3 Substrate Specificity
-
批准号:10228557
-
项目类别:
-
资助金额:$34.24万
-
财政年份:2013
-
负责人:HIROAKI KIYOKAWA
-
依托单位:
Orthogonal Ubiquitin Transfer to Profile E3 Substrate Specificity.
-
批准号:10394033
-
项目类别:
-
资助金额:$0.36万
-
财政年份:2013
-
负责人:HIROAKI KIYOKAWA
-
依托单位:
Role of Cdc25A in breast cancer
-
批准号:7117166
-
项目类别:
-
资助金额:$27.16万
-
财政年份:2005
-
负责人:HIROAKI KIYOKAWA
-
依托单位:
Role of Cdc25A in breast cancer
-
批准号:6986965
-
项目类别:
-
资助金额:$27.81万
-
财政年份:2005
-
负责人:HIROAKI KIYOKAWA
-
依托单位:
Role of Cdc25A in breast cancer
-
批准号:7643883
-
项目类别:
-
资助金额:$26.8万
-
财政年份:2005
-
负责人:HIROAKI KIYOKAWA
-
依托单位:
Role of Cdc25A in breast cancer
-
批准号:8320162
-
项目类别:
-
资助金额:$27.46万
-
财政年份:2005
-
负责人:HIROAKI KIYOKAWA
-
依托单位:
Role of Cdc25A in breast cancer
-
批准号:8677739
-
项目类别:
-
资助金额:$26.5万
-
财政年份:2005
-
负责人:HIROAKI KIYOKAWA
-
依托单位:
Role of Cdc25A in breast cancer
-
批准号:7249334
-
项目类别:
-
资助金额:$26.51万
-
财政年份:2005
-
负责人:HIROAKI KIYOKAWA
-
依托单位:
Role of Cdc25A in breast cancer
-
批准号:8042051
-
项目类别:
-
资助金额:$28.17万
-
财政年份:2005
-
负责人:HIROAKI KIYOKAWA
-
依托单位:
Role of Cdc25A in breast cancer
-
批准号:8519064
-
项目类别:
-
资助金额:$25.68万
-
财政年份:2005
-
负责人:HIROAKI KIYOKAWA
-
依托单位:
Role of Cdc25A in breast cancer
-
批准号:7458812
-
项目类别:
-
资助金额:$26.65万
-
财政年份:2005
-
负责人:HIROAKI KIYOKAWA
-
依托单位:
Role of Cdc25A in breast cancer
-
批准号:8860122
-
项目类别:
-
资助金额:$27.32万
-
财政年份:2005
-
负责人:HIROAKI KIYOKAWA
-
依托单位:
Role of G1-Cdks in immortalization and oncogenesis
-
批准号:6598295
-
项目类别:
-
资助金额:$31.21万
-
财政年份:2003
-
负责人:HIROAKI KIYOKAWA
-
依托单位:
Role of G1-Cdks in immortalization and oncogenesis
-
批准号:7141606
-
项目类别:
-
资助金额:$2.87万
-
财政年份:2003
-
负责人:HIROAKI KIYOKAWA
-
依托单位:
Role of G1-Cdks in immortalization and oncogenesis
-
批准号:7034474
-
项目类别:
-
资助金额:$29.28万
-
财政年份:2003
-
负责人:HIROAKI KIYOKAWA
-
依托单位:
海外基金